Vav2 (VAV2, vav 2 oncogene, Oncogene VAV2, Guanine nucleotide exchange factor, Gef) (Control Peptide)

ETEAKYYRTLEDIEC, internal region\nControl peptide corresponding to polyclonal antibody, Catalog#V2121-11A, goat x human.\n\nVav2 is an oncoprotein member of the Dbl family of proteins that serves as a guanine nucleotide exchange factor (GEF) for the Rho family of Ras-related GTPases (1). Vav2 possesses a C-terminal pleckstrin homology (PH) domain and a tandem Dbl homology (DH) domain which interacts with Rho family GTPases to catalyze GDP release (1-2). The PH\ndomain serves as a negative regulator of DH domain GEF activity, which is promoted by phosphatidylinositol 4, 5-phosphate (PIP2) and is antagonized by the PI3K product, phosphatidylinositol3, 4, 5-phosphate (PIP3) (3). Hence, PI3K may facilitate the activation of Vav. Vav2 also contains a cysteine-rich domain (CRD) that is a positive modulator for DH\ndomain function (4). Vav2 is widely expressed in human tissues (5-6). The SH2 domain of Vav2 associates with the receptor tyrosine kinases EGFr (7-9) and PDGFr (8), binding preferentially to the phosphorylated residues pTyr-992 and pTyr-1148 of EGFr (10) and directly to multiple autophosphorylation sites of PDGFr (8). Overexpression of Vav2 has been shown to be sufficient to activate its oncogenic potential (6). In ovarian tumor cells, the binding of hyaluronan to its receptor (CD44v3) and the recruitment of Grb2 and p185HER2 to the CD44v3-Vav2 complex activates Vav2-mediated Rac1 and Ras signaling, leading to ovarian tumor cell migration and growth.\n\nApplication(s):\nSuitable for use in Peptide ELISA. Other applications have not been tested. \n\nRecommended Dilution:\nOptimal dilutions to be determined by the researcher.\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20 degrees C. Aliquots are stable for at least 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.\n\nPeptide Blocking (see corresponding antibody V2121-11A):\nAntibodies are typically supplied at 0.5mg/ml and peptides as a 100ul pellet. When peptides are reconstituted in 200ul water, the concentration would be also 0.5mg/ml. To start, the best ratio would be 1:1 (which means molar excess of peptides relative to antibodies when identical volumes are mixed). Mix equal volumes of peptide and antibody at the required dilution and leave at ambient temperature. It is best is to have two identical blots, to be incubated with equal amount of antibodies, but one with the antibodies pre-adsorbed to the peptide for 20min. Then incubate and develop the two blots in parallel.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

V2121-11A-P

Size

100ug

Applications

ELISA

Form

Supplied as a lyophilized powder in PBS. Reconstitution: Reconstitute with 200ul sterile ddH2O.

Purity

Highly Purified

References

Henske EP et al. Identification of VAV2 on 9q34 and its exclusion as the tuberous sclerosis gene TSC1. Ann Hum Genet 59 ( Pt 1) :25-37 (1995). PubMed: 7762982.\nGeneral References:\n1. Bustelo, X.R., Mol. Cell Biol. 20: 1461-1477, 2000. 2. Cerione, R.A., Zheng, Y., Curr. Opin. Cell Biol. 8: 216-222, 1996. 3. Han, J., et al., Mol. Cell Biol. 17: 1346-1353, 1997. 4. Booden, M., et al., J. Mol. Cell. Biol. 22: 2487-2497, 2002. 5. Henske, E.P., et al., Ann. Hum. Genet. 59: 25-37, 1995. 6. Schuebel, K.E., et al., Oncogene 13: 363-371, 1996. 7. Liu, B.P., Burridge, K., Mol. Cell. Biol. 20: 7160-7169, 2000. 8. Moores, S.L., et al., Mol. Cell Biol. 20: 6364-6373, 2000. 9. Pandey, A., et al., PNAS USA 97: 179-184, 2000. 10. Tamas, P., et al., J. Biol. Chem. 25: 25, 2002. 11. Bourguignan, L.Y.W., et al., J. Biol. Chem. 276: 48679-48692, 2001.